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Abstract 
Background: Mood disorders are common in oncology patients and inflammation has been pointed 
out as a possible link between depression and cancer. The concentration of the cytokine IL-6 
(Interleukin 6) has been showed to be increased in both depression and cancer. IL-6 is also 
correlated to overall survival in late stage cancer. This study investigates whether IL-6 correlates 
with symptoms of mood disorder, coping capacity, personal growth and common symptoms in 
women with breast cancer. 
Methods: Data from 205 women diagnosed with breast cancer was included in the study. IL-6 
concentrations were determined in serum and symptoms of mood disorder, coping capacity and 
personal growth was measured using Hospital Anxiety and Depression Scale, Sense of Coherence 
Scale and Posttraumatic Growth Inventory respectively. The Memorial Symptom Assessment Scale 
was used to measure both psychological and physiological symptoms. The data was analyzed in 
SPSS with Spearman’s correlation coefficient and Mann-Whitney test. Patients with ongoing MDD 
(Major Depressive Disorder) were excluded. 
Results: IL-6 positively correlated to physiological symptoms in late stage as well as cancer 
progress which is in line with earlier studies. Of the psychological factors measured, positive 
correlations were found between IL-6 and coping capacity, and IL-6 and “Appreciation for Life” in 
the women with early stage breast cancer. 
Conclusion: Our results are in line with the idea that systemic IL-6 correlates with disease stage in 
breast cancer patients, but unlike earlier studies IL-6 does not correlate with symptoms of mood 
disorder. IL-6 might serve as a prognostic marker in more advanced stages of cancer but does not 
seem to have that function in earlier stages of breast cancer. A more refined understanding of how to 
best analyze the relations between our immune system and mood in cancer patients is desirable, as 
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recent research have suggested: omicsbased systems biomedicine methods seem promising for the 
field of inflammation-depression research. 
 
Key words: psychoneuroimmunology, breast cancer, IL-6, mood disorder. 
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Introduction 
There is a growing scientific interest regarding the link between inflammation and mood disorders. 
New articles are being published on the subject every week and recent articles refer to anxiety and 
depression as psychoneuroinflammatory disorders (Miranda et al., 2017). However, the link is not 
fully understood. We know that there is a correlation between mood disorders and inflammation and 
it has been suggested that that it is a bi-directional relationship (Kohler et al., 2017; Passos et al., 
2015; Rosenblat, Cha, Mansur, & McIntyre, 2014). Some of the unanswered questions are if there is 
a causality and if it is true for different types of mood disorders and in different types of patient 
groups. One group of patients that are likely to develop symptoms of mood disorders is the large 
group of people with a cancer disease. The cancer incidence, 2012, was 14.1 million worldwide, 
25% percent of the cancers in women were breast cancer, which is the most common cancer in 
women (Torre et al., 2015). Receiving a cancer diagnosis and battling with the doubts concerning 
treatment, recurrence and mortality is an unimaginable stress. This mental and emotional stress 
combined with the stress of surgery, radiation and chemotherapy puts patients with cancer at a high 
risk of developing inflammation-induced behavioral changes (Miller, Ancoli-Israel, Bower, 
Capuron, & Irwin, 2008).  
Depression is the type of mood disorder most commonly seen in patients with cancer, depending on 
type of instrument used to detect depression, the range in depression prevalence in cancer patients is 
8-24% (Krebber et al., 2014). It is important to differentiate the patients with appropriate sadness 
from receiving a cancer diagnosis from the patients that are developing mood disorders and might 
need extra care and treatment. 
Research resources are being used to find biomarkers for depression and pharmaceutical targets for 
treating mood disorders since it is one of the largest disease group in the world. One link between 
depression and cancer could be inflammatory driven, and this has been investigated in studies 
focusing on cytokines (Oliveira Miranda et al., 2014) ever since Maes in 1995 postulated the 
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hypothesis that IL-1β (Interleukin 1-beta) and IL-6 (Interleukin 6) may be responsible for some of 
the symptoms seen in depression (Maes, 1995). IL-6 has been shown to be elevated in cancer 
patients with depression compared to cancer patients without depression (Jehn et al., 2006). 
In this study we investigate the relation between levels of systemic IL-6 and symptoms of mood 
disorder, symptoms, global symptom distress, symptom burden, coping capacity and posttraumatic 
personal growth in women treated for breast cancer. 
Cytokines - part of our immune system 
Our immune system is described to be divided in two sections: the innate and the adaptive. The 
innate immunity is made up of evolutionary conserved systems of recognition where innate 
leukocytes recognize conserved structures, exogenous Pathogen-Associated Molecular Patterns 
(PAMPs) and endogenous Danger-Associated Molecular Patterns (DAMPs), with their pattern 
recognition receptors (PRRs). PRRs binding to PAMPs or DAMPs activates an inflammatory 
response, pathogen associated or sterile respectively (Fleshner, Frank, & Maier, 2017). When local 
threats are recognized, cytokines are secreted and via the blood-stream activate cells in the liver to 
produce acute phase proteins, such as CRP for example. One of the strongest PAMPs is 
lipopolysaccharide (LPS), an evolutionary conserved molecule that is part of the outer membrane of 
gram-negative bacteria, and many studies on IL-6 response have been performed using LPS-
injections as triggers. Common PRRs are the toll-like receptors (TLRs). TLR4 recognizes LPS and 
starts a signaling cascade with the transcription factor NF-κB, which then starts the transcription of 
cytokines such as IL-1 and IL-6, and tumor necrosis factor alfa (TNF-α).  
These cytokines further drive the inflammation both locally and systemically. Proinflammatory 
cytokines are responsible for the four cardinal symptoms of local inflammation: dolor, calor, rubor 
and tumor (pain, heat, redness and swelling), because they promote increased vascular permeability 
and cellular adhesion. However, IL-6 together with CRP can drive the systemic symptoms of 
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inflammation as well, such as fever, and increased heart and respiratory rate. These changes in 
bodily functions promote quickened healing (Slavich & Irwin, 2014). Cytokines can also affect our 
social behavior towards what is known as sickness behavior, described in animals 1988 by Hart. 
Sickness behavior includes a decrease in daytime activity, disturbances in sleep patterns, loss of 
appetite, and decreased interest in socializing, grooming, mating and hedonic behaviors (Hart, 
1988). Slavich and Irwin (2014) points out the similarity between sickness behavior and the 
behavioral symptoms of depression. They suggest that “These effects thus argue for the possibility 
that cytokines may be able to induce major depression in humans”. They proposed a social signal 
transduction theory of depression, with the background mentioned above, where proinflammatory 
cytokines are the key mediators (Slavich & Irwin, 2014).  
IL-6 
IL-6 is one of the human interleukins, which is a subgroup of cytokines. IL-6 is most commonly 
referred to as a pro-inflammatory cytokine, but it can also act as an anti-inflammatory signal 
molecule depending on its cellular binding sites. The IL-6 receptor (IL-6R) is expressed on 
hepatocytes, megakaryocytes, monocytes, macrophages, B cells and subtypes of T cells. IL-6/IL-6R 
forms a signaling complex via a glycoprotein 130 (gp130) homodimer, using a pathway called 
classic signaling and gives rise to an anti-inflammatory response. The IL-6R can also be in a 
soluble form, sIL-6R, and can then give rise to a pro-inflammatory response via binding to 
membrane bound gp130 which is ubiquitously expressed, using a pathway called trans-signaling. 
Lastly, when the complex IL-6/sIL-6R binds to the soluble form of gp130, trans-signaling will be 
blocked (Hodes, Menard, & Russo, 2016; Wolf, Rose-John, & Garbers, 2014). Because of these 
different responses, little information on the degree of activation of the downstream pathways of  
IL-6 activation is provided by the serum concentrations of IL-6 (Maggio, Guralnik, Longo, & 
Ferrucci, 2006). The trans-signaled pro-inflammatory activity of IL-6 decreases neutrophil and 
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favor mononuclear-cell accumulations, which is proposed to be one of the key factors of 
transitioning from acute to a more chronic inflammation (Lippitz & Harris, 2016).  
IL-6 levels in healthy persons are usually of 1-5 pg/ml, but concentrations of g/ml have been 
measured in patients with sepsis (Wolf et al., 2014). IL-6 levels are higher in patients with cancer, in 
one review (Lippitz & Harris, 2016) the median of serum levels of IL-6 in cancer patients was 6.95 
pg/mL versus 1.31 pg/mL in healthy control groups. 
IL-6 in mood disorder 
In a recent meta-analysis it was concluded that there is an association between IL-6 concentrations 
and major depressive disorder (MDD) (Haapakoski, Mathieu, Ebmeier, Alenius, & Kivimaki, 2015) 
and another meta-analysis investigating inflammatory response to treatment in depression stated 
that IL-6 levels decrease with antidepressant treatment regardless of outcome in treatment result. It 
is also suggested that elevated levels of inflammation contribute to treatment resistance in depressed 
patients (Strawbridge et al., 2015). 
Acute response of IL-6 to a traumatic event may be predicative of the severity of mood disorder. 
Pervanidou et al showed that an elevated plasma level of IL-6 in children after a motor vehicle 
incident was predicative for the development of posttraumatic stress disorder (PTSD) (Pervanidou 
et al., 2007). Hodes et al (2014) have reported that the acute response of IL-6 in rodents correlates 
with the severity of depression symptoms when put under chronic social stress. Furthermore, 
Khandaker et al described that children with higher IL-6 levels had a higher risk of developing 
depression and psychosis(Khandaker, Pearson, Zammit, Lewis, & Jones, 2014). These are all 
examples of IL-6 being predicative of future development of mood disorders. Reichenberg et al also 
showed that LPS-induced higher levels of circulating inflammatory markers (TNF-α, TNF-α 
receptors, IL-6, and IL-1 receptor antagonists) are correlated with higher levels of anxiety and 
depression during the hours immediately following LPS-injection (Reichenberg et al., 2001).  The 
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fact that approximately a third of the patients with MDD are non-responders to the treatments 
available today (Strawbridge et al., 2015) and that MDD is a leading cause of disability worldwide 
(Haapakoski et al., 2015) signals that there is a need for better therapeutic targets or a better 
understanding of the heterogeneity of this patient group. Current evidence suggests that part of this 
heterogeneity can be explained by inflammatory mechanisms (Saad et al., 2014). 
IL-6 and cancer 
Lippitz and Harris conclude in their review of cytokine patterns in cancer patients (2016) that IL-6 
correlates with overall survival independent of the initial tumor histology. However, the IL-6 
increase seems to be a late-stage cancer phenomenon. IL-6 is therefore suggested to be an 
independent possible predicator of survival in cancer. 
Since IL-6 levels correlate with overall survival in cancer patients and it is suggested to reflect the 
cascade of interdependent cytokines involved in the paraneoplastic systemic inflammatory process 
(Lippitz & Harris, 2016), finding new ways to lower IL-6 or its effects could be a way to increase 
the overall survival in cancer patients. Therefore, it is of interest to see if coping capacity, 
psychological symptoms and personal growth correlate to IL-6.  
IL-6 and breast cancer 
Receiving a breast cancer diagnosis is both a physical and a psychological trauma. As is illustrated: 
systemic IL-6 levels have been described to correlate with overall survival in cancer patients, 
symptoms of depression and severity of post-traumatic stress. The effect of IL-6 on breast cancer 
cells is not fully understood. Studies have shown contradictory responses with both inhibitory 
effects on growth and proliferation, and growth promoting effects. To this Dethlefsen (2013) 
suggests in her review that high levels of IL-6, which is showed to correlate with overall survival in 
breast cancer patients, might just be a biomarker of obesity, physical inactivity and impaired 
metabolism (Dethlefsen, Hojfeldt, & Hojman, 2013) . Inflammation is lower in more physically 
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active people (Gleeson et al., 2011) and breast cancer survivors have a marked lower 
cardiorespiratory fitness than their inactive healthy controls (Jones et al., 2012). 
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Aim 
The aim of this study is to investigate whether IL-6 correlates with:  
• symptoms of depression and anxiety (Hospital Anxiety and Depression Scale, HAD) 
• Coping capacity (Sense of Coherence Scale, SOC) 
• Symptoms, total symptom burden and global symptom distress (Memorial Symptom 
Assessment Scale, MSAS) 
• Personal growth (Posttraumatic Growth Inventory, PTGI) 
in women with breast cancer. 
  
11 
 
Methods 
General methods 
This study was done as a part of a larger intervention study, in which the purpose was to determine 
whether Mindfulness Based Stress Reduction (MBSR) therapy could influence mood disorders in 
women with breast cancer. It was carried out as a five-year longitudinal randomized controlled trial 
where the primary outcome, mood disorder, was measured using HAD (Hospital Anxiety and 
Depression scale) and some of the secondary outcomes were IL-6 levels in plasma and the results of 
questionnaires on the participants symptoms and health status (e.g. Sense of Coherence, SOC; 
Memorial Symptom Assesment Scale, MSAS; Posttraumatic Growth Inventory, PTGI).  
This study is investigating the correlation between IL-6 and scores on HAD, MSAS, SOC and PTGI 
in women treated for breast cancer. We also explored the correlation between IL-6 concentration 
and recurrence in breast cancer. 
Data collection and measures 
Socio-demographic data (age, marital status, children, living situation, employment status, 
occupation and educational level) and clinical characteristics (tumor characteristics, type of 
treatment and co-morbidity) was collected through chart reviews and interviews at baseline. 
Blood sampling and self-reported responses with HAD, SOC, MSAS and PTGI used in this study 
was collected at base-line and after 3 months. The results from both observations was added to one 
group and further analyzed as one group. 
Subjects 
Women diagnosed with early stage breast cancer or recurrence in breast cancer were consecutively 
enrolled from two surgical centers in Sweden, Sahlgrenska University Hospital and Skaraborgs 
Hospital. The women were asked to enroll and were informed by research nurses either at their first 
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follow-up appointment for receiving hormonal therapy or at the last treatment with chemotherapy. 
Written and oral information was given about the study. The participants could at any time choose 
to withdraw from the study. Written informed consent was gathered by the women, they were then 
randomized to one of the three groups: MBSR, active controls (MBSR, self-instructing program) or 
non-MBSR. More on the original intervention study on MBSR can be found in Kenne’s study 
design (Kenne Sarenmalm et al., 2013).  
Inclusion criteria 
Women diagnosed with breast cancer: 
receiving hormonal therapy, or; 
after completion of adjuvant chemotherapy, with or without radiotherapy 
Exclusion criteria 
Presence of other advanced illness at diagnosis, and/or: 
ongoing major depression 
ongoing Herceptin therapy 
previous use of the intervention (MBSR) 
Outcomes 
IL-6 
Blood sampling was done in the morning by research nurses. The IL-6 concentrations in serum 
were determined by commercial high sensitivity ELISA kits (R&D Systems, Inc., Abingdon, UK) 
according to the instructions from the manufacturer. 
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Symptoms of mood disorder 
Symptoms of depression and anxiety was measured using the Swedish version of HAD (Hospital 
Anxiety and Depression scale). It is a 14-item questionnaire and contains two subscales: anxiety 
and depression, which can generate 21 scores each.  
Coping capacity 
The professor Aaron Antonovsky developed the Sense of Coherense Scale (SOC), after his research 
for answers to how some people stayed healthy in the concentration camps of World War II. He 
suggested that the way people view their life affects their health, where a strong sense of coherence 
is associated with resources to cope with stressful life events (Eriksson & Lindstrom, 2005). 
The Swedish version of SOC-13 items was used to evaluate the women’s coping capacity. The 
questionnaire is made up of 13 questions with 7-point Likert-type scales to rate the answers. 
Stronger sense of coherence is represented by higher scores (Antonovsky, 1993).  
Symptom experience  
The Memorial Symptom Assessment Scale was used to capture the symptom distress and frequency. 
The scale includes 32 symptoms and scales on frequency, severity and distress of the symptoms in 
the women. Total symptom burden and Global symptom distress index is also generated by the scale 
(Portenoy et al., 1994). 
Personal growth 
Posttraumatic Growth Inventory (PTGI) was used to measure positive life change and personal 
growth. It is a questionnaire with 21 items with 6-point Likert scales. The results can be divided 
into five aspects: Relating to others, new possibilities, personal strength, spiritual change and 
appreciation for life. The PTGI has been shown to be reliable in previous research of women with 
breast cancer. (Tedeschi & Calhoun, 1996)  
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Statistics 
The statistical analyses were performed in IBM SPSS version 22. Spearman’s correlation 
coefficient was used to investigate correlations, and between group comparisons was done using the 
Mann-Whitney test.  
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Ethics 
The study was granted ethical approval by the Ethical Committee, University of Gothenburg D:nr 
499-9; 12/11/2009. Participation in the study was voluntary and the women could always choose to 
discontinue the study. All the data is deidentified and coded, and all the blood samples are kept 
encrypted, only the principal investigator of the original study have access to the code. For more 
ethical considerations regarding the original data please see the study design of the original study 
(Kenne Sarenmalm et al., 2013).  
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Results 
Two hundred and five women, of which 166 women with early stages of breast cancer and 39 was 
diagnosed with a recurrence in breast cancer, admitted our study at baseline and at the three months 
follow-up. Of the 39 women with recurring breast cancer they all started the intervention but five 
patients with recurrence left the study before the follow up at three months due to fatigue, two 
patients with recurrence died before the follow up and one patient did not do the follow up. 
Resulting in a number of 31 women with recurrence assessed the follow up. The women with 
recurrence in breast cancer is in a second RCT-study on the effects of MBSR with the same design 
as the previous by Kenne, results are yet to be published. As different questionnaires, variables and 
blood samples deal with some drop outs and missing data the number of total observations 
including both baseline and follow-up varies between 340 and 410 for different sub-analysis. Due to 
missing data we do not know how many women were asked to participate in the study.  
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Study population, Baseline Data 
 
Table 1. Baseline demographic data and clinical characteristics of the study population.  
Characteristic N % Characteristic N % 
Marital status   Surgery   
   Married/cohabitation 154 75    Mastectomy 105 50.2 
   Widowed 12 5.9    Lumpectomy 97 46.4 
   Divorced 17 8.3    Other 7 3.3 
   Single 15 7.3 Tumor size   
   Partner, not living 
together 
7 3.4    <2 cm 87 44.4 
Living with      2-5 cm 72 36.7 
   Partner 151 73.7    >5 cm 37 18.9 
   Other 2 1.0 Type of cancer   
   Children 12 5.8    Ductal 150 73.2 
   Living alone 40 19.6    Lobular 34 16.6 
Education      Other 21 10.2 
   Primary school 9 4.4 Receptor    
   Secondary school 47 23.0    ER+/PgR+ 134 72.0 
   Lower additional 26 12.7    ER+/PgR- 21 11.3 
   Higher additional 28 13.7    ER-/PgR+ 13 7.0 
   University 95 46.3    ER-/PgR- 18 9.7 
Children   Treatment Postop    
   Yes 184 89.8    Chemotherapy (CT) 107 52.2 
   No 21 10.2    Radiotherapy (RT) 126 61.5 
Employment status      Hormonal therapy (HT) 135 65.9 
   Working 133 68.2    
   Unemployed 1 0.5    
   Disability pensioner 8 4.1    
   Retired 52 26.7    
   Other 1 0.5    
Some of the variables deal with missing data 
IL-6 
Mean serum concentration of IL-6 when all samples were taken together was 2.24 pg/mL (SD 
5.70). When the group was subdivided in patients with early stage breast cancer and patients with 
recurrence there was a significant difference in concentrations of IL-6 (P<0.001). Mean value in the 
early stage breast cancer patients was 1.53 pg/mL (SD 1.3, N=296) and in the group with women 
with recurrence the mean value was 5.58 pg/mL (SD 12.9, N=63), illustrated in figure 1. There were 
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two very high values of IL-6 concentrations in the recurrence group, these are not seen in the figure 
to make it more visually clear. 
 
 
 
 
 
 
 
 
 
 
 
 
  
  Early stage           Recurrence 
Figure 1. IL-6 levels in early stage breast cancer patients and 
patients with recurrence. 
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Psychological outcomes 
Table 2. Psychological outcomes 
Outcome Mean value SD N 
HAD 
 
 
 
   Depression 3.75 3.51 384 
   Anxiety 5.86 4.07 384 
MSAS 
 
  
   Psychological 1.12 0.84 401 
   Physiological 0.61 0.48 401 
   Global Distress Index 1.76 0.76 401 
   Total MSAS 0.68 0.44 401 
Coping capacity 68.3 12.9 384 
PTGI    
   Total Score 57.6 19.6 370 
   Relating to Others 20.7 7.64 375 
   New Possibilities 12.2 5.43 376 
   Personal Strength 11.9 4.35 375 
   Spiritual Change 3.07 2.90 376 
   Appreciation of Life 9.86 3.02 375 
 
Correlations 
Table 3. Correlations between IL-6 and the outcomes of the study 
Outcome Correlation  
Coefficient 
P-value N 
HAD 
   
   Depression -0.044 0.411 350 
   Anxiety -0.048 0.375 350 
MSAS 
   
   Psychological -0.013 0.802 359 
   Physiological 0.173** 0.001 359 
   Global Distress Index 0.073 0.168 359 
   Total MSAS 0.104* 0.050 359 
   Number of Symptoms 0.127* 0.016 359 
Coping capacity 0.086 0.110 350 
PTGI 
   
   Total Score 0.041 0.449 338 
   Relating to Others 0.029 0.596 343 
   New Possibilities -0.043 0.430 344 
   Personal Strength 0.078 0.150 343 
   Spiritual Change -0.034 0.526 344 
   Appreciation of Life 0.133* 0.014 343 
*correlation is significant at the 0.05-level (2-tailed), **correlation is significant at the 0.01-level (2-tailed) 
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There were significant correlations between IL-6 levels and physical symptoms measured with 
MSAS, which was mirrored in the total symptom burden and number of symptoms as well; results 
are presented in table 3.  
We also found a significant positive correlation between IL-6 and “Appreciation of Life”, a sub 
measurement of PTGI, with a correlation coefficient of 0.133 (P = 0.014). The other items regarding 
psychological symptoms gave no significant correlations, presented in table 3. Subanalyses were 
done by dividing the population in patients with early stage breast cancer and patients with 
recurrence, then the correlation between IL-6 and “Appreciation for Life” was stronger in the early 
stage group (correlation coefficient 0.159, P=0.008, N=281) but it was non-significant in the 
recurrence group. A positive correlation was also found between coping capacity and IL-6 in the 
group with early stage breast cancer (correlation coefficient 0.127, P=0.031, N=288).  
When subanalyzing the data in groups divided by recurrence or not, the correlation between IL-6 
and physical symptoms is significant on p<0.001 level in the group with patients with recurrence 
(correlation coefficient 0.433, P=0.000, N=63). However, there was no significant correlation 
between physical symptom, total symptom burden or number of symptoms in the early stage group 
in the subanalysis. The other subanalyses did not show any significant correlations, including 
analysis on HAD-score and IL-6. 
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Discussion 
IL-6, physiological symptoms and disease stage 
Our main result regarding the IL-6 concentrations is that it is significantly higher in the group of 
women with a recurrence in breast cancer. Hence, our data support the idea of a correlation between 
systemic concentrations of IL-6 and a more advanced breast cancer stage (Ma et al., 2017). And as 
Ma et al has suggested, this correlation could be used to detect patients who could be helped from a 
more aggressive therapy. Our findings can be suggested to be in line with the recent proposition that 
IL-6 levels negatively correlate to overall survival in cancer. However, this correlation has only 
been shown in later stages of cancer in earlier studies (Lippitz & Harris, 2016).  
We also found a positive correlation between IL-6 and physiological symptoms in later stages of 
breast cancer. However, there was no correlation between IL-6 and physiological symptoms in the 
group of women with early stage breast cancer.  
IL-6 and psychological symptoms 
In contrast to earlier studies (Seruga, Zhang, Bernstein, & Tannock, 2008) we did not find a 
correlation between IL-6 and cognitive symptoms in our population of patients with cancer.  We did 
not find any correlation between IL-6 and HAD-score neither which has been proposed by recent 
research in patients with colorectal cancer (Miranda et al., 2017). On the other hand, our population 
had lower mean scores on HAD, patients diagnosed with MDD were excluded and the women in 
our study were going through a MBSR-intervention designed to help the women with symptoms of 
mood disorder. This might be part of an explanation to the fact that our result differs from earlier.  
Another explanation to the fact that our findings do not agree with earlier might be that our serum 
levels of IL-6 were lower than the median levels of cancer patients in other studies, the median of 
serum level in cancer patients have been reported as 6.95 pg/mL (Lippitz & Harris, 2016) and our 
median was 2.24 pg/mL. 
Interestingly, the correlation between IL-6 and coping capacity and Appreciation for Life in this 
study, was positive. It has been suggested that measuring IL-6 without measuring sIL-6R cannot 
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give any information on the inflammatory consequences (Maes et al., 2016) and the effects of IL-6 
on tumor growth has not been agreed upon (Dethlefsen et al., 2013). Thus, it may seem fruitless to 
argue whether a positive or negative correlation has any transferability to good or bad in sense of 
inflammatory response or cancer progress. Finding correlations or not is how we move our 
knowledge forward and it seems as we might have come to an edge on the research of how IL-6 on 
its own relates to inflammation, but like all edges it is just the beginning of something new.  
Arguing around our findings one could say that because coping capacity is associated with higher 
resilience to stress it would logically then be negatively correlated to IL-6, since IL-6 is positively 
correlated to depression. High responses in IL-6 concentration to stress is correlated to a higher 
vulnerability to stress (Menard, Pfau, Hodes, & Russo, 2017). Therefore, our results with a positive 
correlation is intriguing, and to our knowledge no one has done this testing before and it would be 
interesting to see if it is reproducible. 
The way forward for inflammation-depression research 
The growing elderly population and improvements in diagnosis and treatment of cancer is resulting 
in a growing population of cancer survivors. This also means that we must deal with more of the 
physical and affective sequelae that often follows cancer diagnosis and treatment. Many cancer 
survivors develop depression, cognitive disturbances, fatigue and sleep disturbances that cannot be 
explained merely by the medical complications of the treatment (Miller et al., 2008). A better 
understanding of the factors affecting the comorbidity in this growing population is highly wanted. 
Psychoneuroimmunology is emerging as a field with possible answers.  
Since 1995 when Michael Maes suggested the inflammatory hypothesis in depression it has been 
the golden standard to measure IL-6 levels as a sign for immune response in patients with mood 
disorders (Maes, 1995; Musselman et al., 2001), but now evidence is emerging pointing away from 
looking at only peripherally IL-6, there is a need for seeing the bigger picture when doing research 
on the immune system and its effects on mood (Maes et al., 2016). The immune system is complex, 
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and we are in a process of learning more on the different pathways. The results have been varying 
on the IL-6 correlation to symptoms of depression in cancer patients, however IL-6 is significantly 
elevated in populations of patients diagnosed with MDD, with or without co-morbidity (Miller et 
al., 2008). 
Hodes et al has been refining the research on how to integrate IL-6 levels into depression diagnosis 
and treatment, by looking at an individual’s peripheral acute IL-6 response to a stimulus. A high 
response in rodents have been correlated with higher susceptibility to development of depression-
like behavior when the rodent is being placed in a situation of social stress or by merely witnessing 
social stress (Hodes et al., 2014). She has also suggested different pathways for IL-6 signaling in 
CNS vs peripherally (Hodes et al., 2016). This is suggesting we could focus more on measuring an 
individual’s IL-6 response to acute stress to predict the psychological burden outcome of chronic 
stress, which living with a cancer diagnosis could be, as an alternative to other suggestions of 
measuring IL-6 and behavior longitudinally to adjust for the fluctuating IL-6 levels over short time 
(Miller et al., 2008). 
Taking the complexity of the immune system into account, the way forward for depression-
inflammation research, with or without comorbidity, should be omics-based and use systems 
biomedicine methodologies to present new possible solutions for prevention and treatment (Maes et 
al., 2016). 
Limitations 
One of the limitations of our study is that the data comes from two observations with the same 
individuals, this may compromise the variation of the IL-6 levels. Other limitations of our study is 
that Body Mass Index (BMI) also affects the IL-6 levels (Felger & Lotrich, 2013) and when doing 
the statistical analysis we did not have this information. However, one recent study showed that 
there were no significant differences in serum IL-6 in breast cancer survivors divided by normal 
weight, over weight and with obesity (Babaei et al., 2015). We also know that physical activity 
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affect IL-6 (Gleeson et al., 2011) and we cannot adjust for this since we do not have any records of 
the subject’s physical activity. Also, infections do increase the IL-6 concentrations, there is no 
excluding of subjects having a minor temporary infection leaving blood samples. Some of the 
physiological symptoms correlating to IL-6 concentrations in our study (cough, nausea, 
breathlessness, difficulty swallowing, diarrhea and loss of appetite) could be signs of ongoing 
infection, thus the infection would be a confounding factor not adjusted for. Our study is also 
limited by the fact that we could not adjust for diet. Diet affects IL-6, one example is that high-fat 
meals increase the concentrations and a Mediterranean diet have been shown to decrease IL-6 
concentrations (Maggio et al., 2006). Our study was also limited because it did not exclude patients 
receiving hormonal therapy, and this can also interfere with IL-6 production (Koka, Petro, & 
Reinhardt, 1998). One could in future analysis do sub analysis dividing the women in groups of 
receiving or not receiving hormonal therapy. Lastly, we do not know if the method measures IL-6 
only or if it also detects IL-6 when bound to sIL-6R and sIL-6R/gp130 and we did not measure sIL-
6R or sGP130, hence we do not know if the anti-inflammatory pathway is upregulated or if the 
transcription is inhibited in a higher or lower proportion. 
Some of the strengths in our study was the large population and that none of the participants had 
ongoing chemotherapy nor trastuzumab (Herceptin) 
 therapy. Chemotherapy can affect IL-6 levels in cancer patients (Jardim Paz et al., 2017) and 
Herceptin was excluded because it was expected to effect the immune system.  Also, some chronic 
diseases (Type 1 diabetes, Crohn’s disease, Rheumatoid Arthritis) may affect the IL-6 
concentrations (Maggio et al., 2006), patients diagnosed with these diseases were excluded since 
they counted as having another advanced illness. 
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Conclusion 
There is a need for finding better tools for an earlier discovery of recurring breast cancer. Our 
results support the idea that systemic IL-6 is positively correlated to disease stage in breast cancer 
patients, which could be regarded as in line with the recent proposal that IL-6, in late stage cancer, 
could be a possible prognostic marker for overall survival in cancer patients and a marker for a 
more advanced disease. 
More and more women are surviving primary breast cancer, but they suffer from sequalae, 
particularly affective symptoms. We need to learn more on how to best care for this group after the 
diagnosis and treatment. Psychoneuroimmunology and breast cancer is an emerging area of interest. 
Research has suggested that IL-6 concentrations positively correlates with symptoms of mood 
disorder in oncology patients, however in this study we did not find this correlation in our 
population of women with breast cancer, patients with ongoing MDD was excluded. A more refined 
understanding of how to best analyze the interplay between our immune system and our behavior 
and mood in cancer patients is desirable. 
We could find positive correlations between IL-6 and coping capacity, and IL-6 and personal 
growth. These results seem inconclusive, and further strengthens the modern idea of a more omics-
based future research where the use of systems biomedicine methodologies could be favorable to 
understand more about our immune system’s involvement in psychological resilience and 
susceptibility to stress.  
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Populärvetenskaplig sammanfattning 
Efter en cancerdiagnos är det vanligt att drabbas av depression. Symtomen för depression är dock 
samma som många av bieffekterna av cancerbehandlingen vilket gör att det är svårt att veta vilka av 
patienterna som behöver hjälp för sina depressiva besvär och vilka som självmant kommer att bli 
bättre efter behandlingen. De senaste decennierna har det forskats på länken mellan vårt 
immunförsvar och depression och man har funnit att cytokinen IL-6 (Interleukin 6) är förhöjd vid 
depression hos cancerpatienter jämfört med patienter som har cancer men inte har en klinisk 
depression. Denna studie har undersökt sambandet mellan IL-6 i blodet och psykologiska och 
fysiologiska symtom hos 208 patienter med bröstcancer uppdelat i tidigt och sent stadie. 
Kvinnorna som hade tidigt stadie av bröstcancer hade mycket lägre IL-6 än kvinnorna som hade 
återfall i bröstcancer. Tidigare har forskare visat att ett högre IL-6 är sämre för den generella 
prognosen vid cancersjukdom. 
Vi hittade en tydlig positiv korrelation mellan IL-6 och fysiologiska symtom hos gruppen med 
återfall. Kvinnorna med tidigt stadie hade lägre IL-6 nivåer än vad patienter med cancer har haft i 
andra studier men här fann vi en positiv korrelation mellan IL-6 och känsla av sammanhang samt 
mot uppskattning av livet. Vi har inte hittat några tidigare studier som utforskat länken mellan 
liknande psykologiska utfall och immunsystemet. Resultatet är intressant och bör testas igen för att 
kunna dra några slutsatser från. Vi fann dock ingen korrelation mellan IL-6 och depressiva symtom 
eller ångest i någon av grupperna, dock hade våra patienter både lägra median IL-6 och mindre 
depressiva besvär än vad populationerna i tidigare studier har haft. 
Forskningsfältet inom immunologi har varit aktivt den senaste tiden och nya upptäckter har gjorts. 
Vi vet nu att IL-6 är mer komplex än vad vi trodde från början, för beroende på vart receptorn som 
binder IL-6 sitter så kommer den att ge en signal som är antingen inflammatorisk eller anti-
inflammatorisk. Detta gör att det är svårt att dra slutsatser om de immunologiska effekterna av IL-6 
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men man kanske kan använda våra resultat för att tidigare hitta patienter med återfall eller se ett 
förhöjt IL-6 som en biomarkör för en svårare sjukdom. 
Att det finns en länk mellan vårt immunsystem och våra beteenden och humör står klart, det forskas 
på detta under benämningen psykoneuroimmunologi. Den framtida forskningen kräver mer 
avancerade metoder för att kunna titta på fler nivåer av immunsvaret så att man kan se vilka gener 
som finns, vilka som uttrycks, vilka av dessa som faktiskt blir till funktionella proteiner och även 
hur dessa sedan metaboliseras i kroppen.  
Kvinnor som lever med en bröstcancerdiagnos blir fler och fler då vi har bättre metoder för att 
upptäcka och behandla. Bröstcancer kan idag ses mer som en kronisk sjukdom och vi behöver lyfta 
forskningen till hur vi bäst tar hand om den växande gruppen av överlevare och hur vi snabbt hittar 
de som får återfall.  
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